Functional characterization of c-Mpl ectodomain mutations that underlie congenital amegakaryocytic thrombocytopenia

Growth Factors

Volumn 32, Issue 1, 2014, Pages 18-26

  Varghese, Leila N ^a,b   Zhang, Jian Guo ^a,b   Young, Samuel N ^a   Willson, Tracy A ^a,b   Alexander, Warren S ^a,b   Nicola, Nicos A ^a,b   Babon, Jeffrey J ^a,b   Murphy, James M ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Congenital amegakaryocytic thrombocytopenia; Ligand binding; Mpl; TPO

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE RECEPTOR; EPITOPE; PROTEIN C MPL; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL STRAIN COS7; CELL SURFACE; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; CONTROLLED STUDY; GENE MUTATION; LIGAND BINDING; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; THROMBOCYTOPENIA;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BLOOD PLATELETS; CELL LINE; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; MEGAKARYOCYTES; MICE; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PROLACTIN; RECEPTORS, THROMBOPOIETIN; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 84893336505     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2013.874347     Document Type: Article

References (49)

1. Abkowitz JL, Chen J. 2007. Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. Blood 109:5186-5190.
2. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. 1996. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87:2162-2170.
3. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, et al. 2001. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 97:139-146.
4. Bass SH, Mulkerrin MG, Wells JA. 1991. A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc Natl Acad Sci USA 88:4498-4502.
5. Bazan JF. 1990. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 87:6934-6938.
6. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. 1997. Human platelets display high-affinity receptors for thrombopoietin. Blood 89:1896-1904.
7. Chen J, Olsen J, Ford S, Mirza S, Walker A, Murphy JM, Young IG. 2009. A new isoform of interleukin-3 receptor {alpha} with novel differentiation activity and high affinity binding mode. J Biol Chem 284:5763-5773.
8. Chung HS, Koh KN, Kim HJ, Lee KO, Park CJ, Chi HS, Kim SH, et al. 2011. A novel nonsense mutation in the MPL gene in congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 56: 304-306.
9. Clackson T, Wells JA. 1995. A hot spot of binding energy in a hormonereceptor interface. Science 267:383-386.
10. de Vos AM, Ultsch M, Kossiakoff AA. 1992. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 255:306-312.
11. Debili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, Schooley K, et al. 1995a. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 85: 391-401.
12. Debili N, Wendling F, Katz A, Guichard J, Breton-Gorius J, Hunt P, Vainchenker W. 1995b. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 86:2516-2525.
13. Drachman JG, Griffin JD, Kaushansky K. 1995. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 270:4979-4982.
14. Fox NE, Chen R, Hitchcock I, Keates-Baleeiro J, Frangoul H, Geddis AE. 2009. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: Functional characterization and a review of the literature. Exp Hematol 37:495-503.
15. Fox NE, Lim J, Chen R, Geddis AE. 2010. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: Proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents. Exp Hematol 38:384-391.
16. Gandhi MJ, Pendergrass TW, Cummings CC, Ihara K, Blau CA, Drachman JG. 2005. Congenital amegakaryocytic thrombocytopenia in three siblings: Molecular analysis of atypical clinical presentation. Exp Hematol 33:1215-1221.
17. Germeshausen M, Ballmaier M, Welte K. 2006. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: The type of mutation predicts the course of the disease. Hum Mutat 27:296.
18. Gluzman Y. 1981. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175-182.
19. Hercus TR, Barry EF, Dottore M, McClure BJ, Webb AI, Lopez AF, Young IG, et al. 2013. High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties. PLoS ONE 8:e74376.
20. Hilton DJ, Watowich SS, Katz L, Lodish HF. 1996. Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor. J Biol Chem 271:4699-4708.
21. Hobbs S, Jitrapakdee S, Wallace JC. 1998. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252:368-372.
22. Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T. 1999. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 96: 3132-3136.
23. Kimura S, Roberts AW, Metcalf D, Alexander WS. 1998. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 95:1195-1200.
24. Lock P, Metcalf D, Nicola NA. 1994. Histidine-367 of the human common beta chain of the receptor is critical for high-affinity binding of human granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 91:252-256.
25. Middleton SA, Barbone FP, Johnson DL, Thurmond RL, You Y, McMahon FJ, Jin R, et al. 1999. Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide. J Biol Chem 274:14163-14169.
26. Middleton SA, Johnson DL, Jin R, McMahon FJ, Collins A, Tullai J, Gruninger RH, et al. 1996. Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family. J Biol Chem 271:14045-14054.
27. Miller J, Malek TR, Leonard WJ, Greene WC, Shevach EM, Germain RN. 1985. Nucleotide sequence and expression of a mouse interleukin 2 receptor cDNA. J Immunol 134:4212-4217.
28. Mirza S, Chen J, Wen B, Ewens CL, Dai J, Murphy JM, Young IG. 2010a. Two modes of beta-receptor recognition are mediated by distinct epitopes on mouse and human interleukin-3. J Biol Chem 285: 22370-22381.
29. Mirza S, Walker A, Chen J, Murphy J, Young I. 2010b. The Ig-like domain of human GM-CSF receptor a plays a critical role in cytokine binding and receptor activation. Biochem J 426:307-317.
30. Muraoka K, Ishii E, Tsuji K, Yamamoto S, Yamaguchi H, Hara T, Koga H, et al. 1997. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol 96:287-292.
31. Murphy JM, Ford SC, Olsen JE, Gustin SE, Jeffrey PD, Ollis DL, Young IG. 2004. Interleukin-3 binding to the murine betaIL-3 and human betac receptors involves functional epitopes formed by domains 1 and 4 of different protein chains. J Biol Chem 279:26500-26508.
32. Murphy JM, Ford SC, Wiedemann UM, Carr PD, Ollis DL, Young IG. 2003. A novel functional epitope formed by domains 1 and 4 of the human common beta-subunit is involved in receptor activation by granulocyte macrophage colony-stimulating factor and interleukin 5. J Biol Chem 278:10572-10577.
33. Murphy JM, Soboleva TA, Mirza S, Ford SC, Olsen JE, Chen J, Young IG. 2008. Clarification of the role of N-glycans on the common betasubunit of the human IL-3, IL-5 and GM-CSF receptors and the murine IL-3 beta-receptor in ligand-binding and receptor activation. Cytokine 42:234-242.
34. Murphy JM, Young IG. 2006. IL-3, IL-5, and GM-CSF signaling: Crystal structure of the human beta-common receptor. Vitam Horm 74:1-30.
35. Palacios R, Steinmetz M. 1985. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germline configuration, and generate B lymphocytes in vivo. Cell 41: 727-734.
36. Passos-Coelho JL, Sebastiao M, Gameiro P, Reichert A, Vieira L, Ferreira I, Miranda N, et al. 2007. Congenital amegakaryocytic thrombocytopenia - report of a new c-mpl gene missense mutation. Am J Hematol 82:240-241.
37. Pemberton LC, Levett D, Skinner R, Hall AG, Hanley JP. 2006. Novel mutations in a child with congenital amegakaryocytic thrombocytopenia. Br J Haematol 135:742-743.
38. Rost B, Yachdav G, Liu J. 2004. The PredictProtein server. Nucleic Acids Res 32:W321-W326.
39. Sabath DF, Kaushansky K, Broudy VC. 1999. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 94:365-367.
40. Savoia A, Dufour C, Locatelli F, Noris P, Ambaglio C, Rosti V, Zecca M, et al. 2007. Congenital amegakaryocytic thrombocytopenia: Clinical and biological consequences of five novel mutations. Haematologica 92:1186-1193.
41. Schipper LF, Brand A, Reniers NC, Melief CJ, Willemze R, Fibbe WE. 1998. Effects of thrombopoietin on the proliferation and differentiation of primitive and mature haemopoietic progenitor cells in cord blood. Br J Haematol 101:425-435.
42. Shi J, Blundell TL, Mizuguchi K. 2001. FUGUE: Sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. J Mol Biol 310:243-257.
43. Steinberg O, Gilad G, Dgany O, Krasnov T, Zoldan M, Laor R, Kapelushnik J, et al. 2007. Congenital amegakaryocytic thrombocytopenia- 3 novel c-MPL mutations and their phenotypic correlations. J Pediatr Hematol Oncol 29:822-825.
44. Stoddart MT, Connor P, Germeshausen M, Ballmaier M, Steward CG. 2013. Congenital amegakaryocytic thrombocytopenia (CAMT) presenting as severe pancytopenia in the first month of life. Pediatr Blood Cancer 60:E94-E96.
45. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, et al. 1998. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395:511-516.
46. Tijssen MR, di Summa F, van den Oudenrijn S, Zwaginga JJ, van der Schoot CE, Voermans C, de Haas M. 2008. Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia. Br J Haematol 141:808-813.
47. van den Oudenrijn S, Bruin M, Folman CC, Peters M, Faulkner LB, de Haas M, von dem Borne AE. 2000. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 110:441-448.
48. Woodcock JM, Zacharakis B, Plaetinck G, Bagley CJ, Qiyu S, Hercus TR, Tavernier J, et al. 1994. Three residues in the common beta chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF. EMBO J 13:5176-5185.
49. Zhang JL, Simeonowa I, Wang Y, Sebald W. 2002. The high-affinity interaction of human IL-4 and the receptor alpha chain is constituted by two independent binding clusters. J Mol Biol 315:399-407.